IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2025

Aggregated presentation by day and by market



Statement of transactions in own shares from 1st September to 5th September 2025
       
Name of the issueIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket         (MIC Code)
 IPSEN549300M6SGDPB4Z94P1101/09/2025FR0010259150   632116,87753AQEU 
 IPSEN549300M6SGDPB4Z94P1101/09/2025FR0010259150  1 200116,94167CCXE 
 IPSEN549300M6SGDPB4Z94P1101/09/2025FR0010259150   200116,90TQEX 
 IPSEN549300M6SGDPB4Z94P1101/09/2025FR0010259150  2 606117,18388XPAR 
 IPSEN549300M6SGDPB4Z94P1102/09/2025FR0010259150   300116,20AQEU 
 IPSEN549300M6SGDPB4Z94P1102/09/2025FR0010259150   500116,20CCXE 
 IPSEN549300M6SGDPB4Z94P1102/09/2025FR0010259150   200116,286TQEX 
 IPSEN549300M6SGDPB4Z94P1102/09/2025FR0010259150  3 600116,41622XPAR 
 IPSEN549300M6SGDPB4Z94P1103/09/2025FR0010259150   300116,70AQEU 
 IPSEN549300M6SGDPB4Z94P1103/09/2025FR0010259150   600116,68333CCXE 
 IPSEN549300M6SGDPB4Z94P1103/09/2025FR0010259150   300116,50967TQEX 
 IPSEN549300M6SGDPB4Z94P1103/09/2025FR0010259150  3 400116,95335XPAR 
 IPSEN549300M6SGDPB4Z94P1104/09/2025FR0010259150  1 200120,00CCXE 
 IPSEN549300M6SGDPB4Z94P1104/09/2025FR0010259150  3 400119,88147XPAR 
 IPSEN549300M6SGDPB4Z94P1105/09/2025FR0010259150   300120,00 €AQEU 
 IPSEN549300M6SGDPB4Z94P1105/09/2025FR0010259150   600120,05CCXE 
 IPSEN549300M6SGDPB4Z94P1105/09/2025FR0010259150   300120,00TQEX 
 IPSEN549300M6SGDPB4Z94P1105/09/2025FR0010259150  3 400119,80815XPAR 
       23 038118,01642  
         





Attachment



EN
09/09/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

19h / 45m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

19h / 45m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch